.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

ADA

Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says

June 20th 2020

Article

There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.

Biosimilar Insulin Glargine Shows Pharmacokinetic and Pharmacodynamic Equivalence to the Originator

June 15th 2017

Article

The study pesented at the American Diabetes Association 77th Scientific Sessions compared Mylan/Biocon’s MYL-1501D, a proposed biosimilar to Sanofi-Aventis’ insulin glargine, with the reference product.

Study Finds Significant Differences in Glycemic Control Between Reference and Biosimilar Morning Insulin

June 14th 2017

Article

In order to investigate the best morning insulin therapy to improve glycemic variability in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar.